InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

Current share price for MYX : $2.710 0.02 (0.73%)+

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$220 Mayne Pharma appoints new Chief Financial Officer 17 Jul 2026 8:53AM $2.920 $2.710 fallen by 7.19%
$220 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.710 fallen by 2.87%
$220 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.710 fallen by 2.87%
$220 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.710 fallen by 2.87%
$220 Notification regarding unquoted securities - MYX 7 Jul 2026 8:16AM $2.790 $2.710 fallen by 2.87%
$220 Initial Director's Interest Notice 1 Jul 2026 9:38AM $2.790 $2.710 fallen by 2.87%
$220 Mayne Pharma appoints new Non-Executive Director 26 Jun 2026 9:15AM $2.390 $2.710 risen by 13.39%
$220 Change in substantial holding 26 Jun 2026 9:11AM $2.390 $2.710 risen by 13.39%
$220 Change in substantial holding 18 Jun 2026 2:57PM $2.320 $2.710 risen by 16.81%
$220 Final Director's Interest Notice 5 Jun 2026 3:51PM $2.315 $2.710 risen by 17.06%
$220 Mayne Pharma receives $14.4m for legal costs from Cosette 5 Jun 2026 10:44AM $2.210 $2.710 risen by 22.62%
$220 MYX Jefferies Global Healthcare Conference Presentation 4 Jun 2026 5:17PM $2.210 $2.710 risen by 22.62%
$220 New DistributeRx partnership with Resilia Pharmaceuticals 1 Jun 2026 8:50AM $2.400 $2.710 risen by 12.92%
$220 Mayne Pharma to present at Jefferies Healthcare Conference 27 May 2026 8:44AM $2.340 $2.710 risen by 15.81%
$220 Court awards MYX $13.27m for legal costs from Cosette 22 May 2026 11:08AM $2.335 $2.710 risen by 16.06%
$220 Mayne Pharma announces expansion of Adelaide Apothecary 18 May 2026 8:57AM $2.310 $2.710 risen by 17.32%
$220 Mayne Pharma 3Q investor presentation 7 May 2026 9:14AM $2.620 $2.710 risen by 3.44%
$220 Notification of cessation of securities - MYX 4 May 2026 5:25PM $2.810 $2.710 fallen by 3.56%
$220 Further details re equity instruments to be issued to CEO 30 Apr 2026 8:22AM $2.870 $2.710 fallen by 5.57%
$220 Mayne Pharma reports unaudited 3Q FY26 results 29 Apr 2026 9:33AM $2.690 $2.710 risen by 0.74%
$220 MYX expects no material impact from US s232 tariffs 7 Apr 2026 9:41AM $2.330 $2.710 risen by 16.31%
$220 Non-Executive Director retirement and recruitment 2 Apr 2026 12:33PM $2.395 $2.710 risen by 13.15%
$220 Ceasing to be a substantial holder 31 Mar 2026 4:38PM $2.270 $2.710 risen by 19.38%
$220 Becoming a substantial holder 27 Mar 2026 4:46PM $2.280 $2.710 risen by 18.86%
$220 Mayne Pharma ASX SMIDcaps conference presentation 25 Mar 2026 11:12AM $2.300 $2.710 risen by 17.83%

1 - 25 of 881 results

Page 1 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.